Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (848)	10/19/1998 7:47:00 PM
From: Dave K	Respond to of 887

"It is clear however, that we're getting screwed". I and other investors agree 100%. This is insult to injury ! Disgusting how some management of these venture companies come to market, take zero risk, milk it with high pay & options, and then will stick it to the outsiders in the end. Good luck to these small companies and their bankers trying to raise capital in the future.

To: Dr. John M. de Castro who wrote (848)	10/19/1998 10:41:00 PM
From: rkrw	Read Replies (2) \| Respond to of 887

John, I'm going to take the opposite stance on the deal. If anyone here had faith in DEPO and their mgt to lead the company to success, they must not have been watching very closely or must be eternal optimists. You all should be looking at what DEPO shareholders are getting, shares in Skyepharma and what the prospects of Skyepharma are, rather than fretting that DEPO isn't getting enough. I don't know too much about Skye but I do know they are creating a broad drug delivery platform covering oral drugs, inhalation (recent deal with Sepr) and now have sustained release injectables via Depo. DEPO is in a very weak position. Book value is a meaningless factor here. Cash position is extremely poor. Based on last quarters burn, DEPO has a whopping 2 months of cash left. In this market, as Dave alludes to, good luck raising capital. Staying independent and raising cash with the shares treading at a buck is not a reasonable option. Best bet was to sell out for shares in hopefully a company that is better managed, has better prospects and has a keen eye on enhancing shareholder value. Seeing Skyepharma is a very young and newly public company this has yet to be determined however from watching DEPO for the last year, I believe they are better off in SkyePharma's (or anyone elses) hands. Good luck.